Sangamo Therapeutics(SGMO)

泼天财富我自来07-26 10:27

$Sangamo Therapeutics(SGMO)$ 补充更新一下
2024/7/24 该公司公布和辉瑞合作开发血友病基因药物三期达标，股价暴涨，后续可期！查看全文

产业链观察07-24 21:24

#药闻简讯# 2024 年 7 月 24 日，$辉瑞(PFE)$ 今天宣布了评估giroctocogene fitelparvovec的3期研究（NCT04370054）的积极顶线结果，该研究是一种用于治疗中度至重度血友病A成人的研究性基因疗法。$Sangamo Therapeutics(SGMO)$查看全文

当期报告

Sangamo Therapeutics(SGMO)2023-11-04 04:05

$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-23-036697  Act: 34  Size: 1 MB 网页链接查看全文

员工持股计划

Sangamo Therapeutics(SGMO)2023-08-09 04:55

$Sangamo Therapeutics(SGMO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-206301  Act: 33  Size: 73 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)2023-08-30 04:25

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-047586  Size: 6 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)2023-08-30 04:25

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-047590  Size: 6 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)01-25 05:45

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001756  Size: 6 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)01-25 05:45

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001754  Size: 6 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)01-25 05:45

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001755  Size: 6 KB 网页链接查看全文

其他

Sangamo Therapeutics(SGMO)04-20 04:25

$Sangamo Therapeutics(SGMO)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102893  Act: 34  Size: 17 MB 网页链接查看全文

chuminhua2019-12-11 16:06

12/7，在ASH年会上，Sangamo Therapeutics公司$Sangamo Therapeutics(SGMO)$ 和辉瑞（Pfizer）公司$辉瑞(PFE)$ 联合公布了治疗严重A型血友病的基因疗法SB-525在名为Alta的1/2期临床试验中的中期结果。试验结果表明，所有接受最高剂量SB-525治疗的患者，血液中凝血因子VIII的水平都达到了正常范围。...查看全文

张小丰2019-12-10 22:42

$Sangamo Therapeutics(SGMO)$ 血友病A的数据还行啊。有一个病人出现波动。结果股票连续暴跌2天。。
我自己的判断是这药的效果和Biomaine的差不多的。目前靶向肝脏的基因疗法按照理论上来看就不是一发管终生，更像是一发管8年。。。SGMO的疗法未来跟踪时间长了也会慢慢衰退。查看全文

Gin_Eos2019-07-10 00:04

$Sangamo Therapeutics(SGMO)$ 九块多的成本，昨晚十三块多清仓换成了Moderna，看看这次的操作结果～查看全文

用户48783635432019-07-09 10:43

【辉瑞和Sangamo治疗A型血友病基因疗法试验结果良好，缩小与BioMarin差距】辉瑞$辉瑞(PFE)$ 及其合作伙伴Sangamo$Sangamo Therapeutics(SGMO)$ 开发的基因疗法SB-525早期试验结果显示，10名患者接受4种不同剂量的SB-525治疗，剂量越高，体内产生的凝血蛋白就越多，两名患者接受治疗6个月后甚至达到...查看全文

Zuluzulu2019-07-06 14:11

Sangamo backs up early success for hemophilia gene therapy
By Andrew Dunn
Published July 5, 2019
网页链接
$Sangamo Therapeutics(SGMO)$查看全文

Zuluzulu2019-05-23 19:42

May 22, 2019
Biomarin hopes long-term valrox data can stem the bleeding
网页链接
$拜玛林制药(BMRN)$ $Sangamo Therapeutics(SGMO)$查看全文

Zuluzulu2019-05-20 13:26

Sangamo掌控ZFN基因编辑专利十余年，B型血友病临床试验迎来首位患者，全球ZFN临床进展如何
陈婉仪 基因药物 今天
网页链接
$Sangamo Therapeutics(SGMO)$查看全文

Zuluzulu2019-04-04 18:08

Does Sangamo Have the Best Gene Therapy Program Now?
The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Cory Renauer (TMFang4apples)
Apr 3, 2019 at 8:13AM
网页链接查看全文

Zuluzulu2019-04-02 19:34

Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
‒ Conference call and webcast scheduled for 8:00 a.m. Eastern Time today
网页链接查看全文

Zuluzulu2019-04-02 19:27

Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
April 2, 2019 at 7:00 AM EDT
网页链接
$Sangamo Therapeutics(SG...查看全文

上行空间均超50%，RBC力荐这三只潜力股

智通财经APP获悉，近期，RBC针对Verrica Pharmaceuticals(VRCA.US)、Sangamo Therapeutics(SGMO.US)、GooseHead Insurance(GSHD.US)三家公司发表研报，并强调了这三只股票未来强劲的长期增长前景，预计在未来一年的上行空间将至少达到50... 网页链接

当期报告

$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-24-032815  Act: 34  Size: 287 KB 网页链接

超过5%股东持股披露「修订」

$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001086364-24-008122  Act: 34  Size: 12 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016686  Size: 6 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015752  Size: 8 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015753  Size: 7 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015754  Size: 7 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015755  Size: 8 KB 网页链接

当期报告

$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 5.02, 5.03, 5.07, and 9.01 Accession Number: 0001628280-24-026903  Act: 34  Size: 13 MB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014796  Size: 9 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014798  Size: 9 KB 网页链接